NCT06277934View on ClinicalTrials.gov

A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

March 8, 2024

Primary Completion Date

August 13, 2024

Study Completion Date

August 13, 2024

Conditions
Obesity
Interventions
DRUG

RGT001-075

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (10)

13850

Velocity Clinical Research, Vestal

27701

Velocity Clinical Research, Durham

44122

Velocity Clinical Research, Cleveland

46383

Velocity Clinical Research, Valparaiso

68134

Velocity Clinical Research, Omaha

75230

Velocity Clinical Research, Dallas

84088

Velocity Clinical Research, West Jordan

90057

Velocity Clinical Research, Los Angeles

97504

Velocity Clinical Research, Medford

02818

Velocity Clinical Research, East Greenwich

All Listed Sponsors
lead

Regor Pharmaceuticals Inc.

INDUSTRY

NCT06277934 - A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities | Biotech Hunter | Biotech Hunter